31 March 2026 in PERSONALITY IN A CHANGING WORLD: HEALTH, ADAPTATION, DEVELOPMENT
Background. Anxiety and depression often complicate the postoperative period in cardiac surgery patients, worsening their quality of life. Standard therapy is not always sufficiently effective or has limitations, which determines the relevance of searching for non-drug correction methods, including those using virtual reality (VR) technologies. Aim. To study the effectiveness of the combined use of VR and binaural beats (BB) for reducing anxiety and depression levels in patients in the early postoperative period of coronary artery bypass grafting (CABG). Methods. A controlled study included 200 patients after CABG with signs of anxiety and depression. Using simple randomization, an experimental group (n=100, a 14-day course of VR relaxation combined with BB at frequency of 11-12 Hz) and a control group (n=100, standard therapy only) were formed. Psychodiagnostics was performed using the Beck Anxiety and Depression Inventories, the HADS, the SOM PAI Somatic Symptom Scale, the Cognitive Avoidance Questionnaire (CAQ), and the Spielberger-Khanin State-Trait Anxiety Inventory before and after the intervention. Results. The experimental group showed a statistically significant decrease in scores on the Hospital Anxiety Scale (from 16 to 11), the Beck Anxiety Inventory (from 36 to 32) and Beck Depression Inventory (from 28 to 24), as well as state anxiety (from 46 to 38) (p <0.001). In the control group, the positive dynamics were less pronounced. Conclusion. The combined use of virtual reality technologies and binaural beats is an effective additional method for correcting anxiety and depressive states in patients after CABG, contributing to the improvement of psychoemotional status during the rehabilitation process.
30 December 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Objective. Study of the efficacy of ampakins (Ampasse) in patients with anxiety and depressive disorders in the early recovery period of ischemic stroke (IS). Material and methods. The study included 203 patients with IS in the early recovery period who underwent rehabilitation measures at the Doctor Clinic medical facility (Tuimazy, Republic of Bashkortostan) in the period from January 2023 to August 2025. The study included patients with a history of IS no later than 3—6 months before the start date of the study, with signs of anxiety and depression of varying severity, who scored at least 8 points but no higher than 10 (the level of subclinically expressed symptoms) on the hospital anxiety and depression scale (HADS), as well as those who scored the required number of points on The Montreal Cognitive Function Assessment Scale (MoCA) (at least 10 points). The patients who met the inclusion criteria were randomly assigned to two groups: the experimental group and the control group. In the experimental group, 102 patients received Ampasse therapy in addition to standard therapy. The average age of these patients was 63±8.9 years, 48 of whom were women and 54 were men. In the control group, 101 patients received only basic therapy. The average age of the patients was 66±8.1 years), there were 45 women and 56 men. Throughout the study, the Beck anxiety, Beck depression, HADS, and the Spielberger-Khanin anxiety scales were also used. Results. The dynamics of improvement on all psychometric scales in the experimental group was statistically and clinically more pronounced than in the control group, which received only standard treatment. Conclusion. The results of this study demonstrated the positive effect of Ampasse on reducing the symptoms of anxiety and depression in patients after undergoing AI in the early recovery period.